112 related articles for article (PubMed ID: 27628460)
1. Monitoring anticoagulation with argatroban in critically ill patients: activated partial thromboplastin time versus diluted thrombin time.
Keyl C; Lehane C; Zimmer E; Trenk D
Thromb Haemost; 2016 Nov; 116(6):1180-1181. PubMed ID: 27628460
[No Abstract] [Full Text] [Related]
2. Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.
Treschan TA; Schaefer MS; Geib J; Bahlmann A; Brezina T; Werner P; Golla E; Greinacher A; Pannen B; Kindgen-Milles D; Kienbaum P; Beiderlinden M
Crit Care; 2014 Oct; 18(5):588. PubMed ID: 25344113
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of Argatroban in Critically Ill Patients: A Prospective Study Comparing Activated Partial Thromboplastin Time, Point-of-Care Viscoelastic Testing with Ecarin Clotting Time and Diluted Thrombin Time to Mass Spectrometry.
Heubner L; Oertel R; Tiebel O; Mehlig-Warnecke N; Beyer-Westendorf J; Mirus M; Roessler M; Renner B; Spieth PM
Anesthesiology; 2024 Feb; 140(2):261-271. PubMed ID: 37787760
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
[TBL] [Abstract][Full Text] [Related]
5. Argatroban anticoagulation in critically ill patients.
Beiderlinden M; Treschan TA; Görlinger K; Peters J
Ann Pharmacother; 2007 May; 41(5):749-54. PubMed ID: 17440009
[TBL] [Abstract][Full Text] [Related]
6. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
Guy S; Kitchen S; Maclean R; Van Veen JJ
Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
[TBL] [Abstract][Full Text] [Related]
7. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia.
Keegan SP; Gallagher EM; Ernst NE; Young EJ; Mueller EW
Ann Pharmacother; 2009 Jan; 43(1):19-27. PubMed ID: 19116377
[TBL] [Abstract][Full Text] [Related]
8. Alternative monitoring of argatroban using plasma-diluted thrombin time.
Wanat MA; Hart SR; Putney D; Liebl MG; Chandler W
Ann Pharmacother; 2013 Apr; 47(4):e18. PubMed ID: 23482736
[TBL] [Abstract][Full Text] [Related]
9. More on the Limitations of the Activated Partial Thromboplastin Time for Monitoring Argatroban Therapy.
Guy S; Van Veen J; Kitchen S
Semin Thromb Hemost; 2017 Sep; 43(6):642-643. PubMed ID: 28618436
[No Abstract] [Full Text] [Related]
10. Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia.
Keyl C; Zimmer E; Bek MJ; Wiessner M; Trenk D
Thromb Haemost; 2016 Jun; 115(6):1081-9. PubMed ID: 26792118
[TBL] [Abstract][Full Text] [Related]
11. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia.
Reichert MG; MacGregor DA; Kincaid EH; Dolinski SY
Ann Pharmacother; 2003 May; 37(5):652-4. PubMed ID: 12708939
[TBL] [Abstract][Full Text] [Related]
12. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.
Gray A; Wallis DE; Hursting MJ; Katz E; Lewis BE
Clin Appl Thromb Hemost; 2007 Oct; 13(4):353-61. PubMed ID: 17911186
[TBL] [Abstract][Full Text] [Related]
13. A case series describing the use of argatroban in patients on extracorporeal circulation.
Cornell T; Wyrick P; Fleming G; Pasko D; Han Y; Custer J; Haft J; Annich G
ASAIO J; 2007; 53(4):460-3. PubMed ID: 17667231
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
Dang CH; Durkalski VL; Nappi JM
Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
[TBL] [Abstract][Full Text] [Related]
15. Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study.
Scalambrino E; Padovan L; Chantarangkul V; Clerici M; Artoni A; Peyvandi F; Tripodi A
Int J Lab Hematol; 2020 Jun; 42(3):e128-e131. PubMed ID: 32086868
[No Abstract] [Full Text] [Related]
16. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
Kiser TH; Jung R; MacLaren R; Fish DN
Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
[TBL] [Abstract][Full Text] [Related]
17. Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban.
Guy S; Kitchen S; Van Veen JJ
Br J Haematol; 2018 Feb; 180(4):594-597. PubMed ID: 27785784
[No Abstract] [Full Text] [Related]
18. Efficacy of argatroban in critically ill patients with heparin resistance: a retrospective analysis.
Treichl B; Bachler M; Lorenz I; Friesenecker B; Oswald E; Schlimp CJ; Pedross F; Fries D
Semin Thromb Hemost; 2015 Feb; 41(1):61-7. PubMed ID: 25594496
[TBL] [Abstract][Full Text] [Related]
19. Argatroban for anticoagulation in continuous renal replacement therapy.
Link A; Girndt M; Selejan S; Mathes A; Böhm M; Rensing H
Crit Care Med; 2009 Jan; 37(1):105-10. PubMed ID: 19050602
[TBL] [Abstract][Full Text] [Related]
20. Response to: "More on the Limitations of the aPTT for Monitoring Argatroban Therapy".
Van Cott EM; Roberts AJ; Dager WE
Semin Thromb Hemost; 2017 Sep; 43(6):644. PubMed ID: 28609797
[No Abstract] [Full Text] [Related]
[Next] [New Search]
